STEPHANIE FISH: Open Payments
NPI 1952741845 · MELBOURNE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,362 in 138 payments from 14 companies in 2025. Trend: 2023 $2,526 · 2024 $2,439 · 2025 $2,362
Food & beverage: $2,362
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 31 | $490 |
| ABBVIE INC. | 26 | $335 |
| Alkermes, Inc. | 15 | $261 |
| E.R. Squibb & Sons, L.L.C. | 15 | $234 |
| Otsuka America Pharmaceutical, Inc. | 12 | $205 |
| Neurocrine BioSciences, Inc. | 11 | $194 |
| Axsome Therapeutics, Inc. | 8 | $167 |
| Vanda Pharmaceuticals Inc. | 3 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $86 |
| Luye Pharma (USA) Ltd. | 3 | $82 |
Products named: CAPLYTA, VRAYLAR, COBENFY, ARISTADA, INGREZZA, Auvelity, ABILIFY ASIMTUFII, FANAPT.
Industry payments across FL — which companies pay providers there.
